Patrick A. McBrayer is President and Chief Executive Officer of AxioMed™ Spine Corporation of Garfield Heights, Ohio. AxioMed is a medical device company focused on restoring the native function of the spine.
Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He is also a Founder of Transave Inc., a biotechnology company focused on the site specific treatment of lung disease. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999.
Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology. In both companies he was responsible for a number of private placements and both companies public offerings and led these organizations to dominant market share positions. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.
He has over 20 years healthcare senior management experience and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. A 1974 graduate of the United States Military Academy, Mr. McBrayer also served on West Point's Association of Graduates Board of Trustees.
Mr. Kuras has 20 years of medical device development experience, his primary focus being device and market development in the orthopedic spinal area. He has development experience in the both class II and class III devices and demonstrated proficiency in developing, implementing and executing strategic business plans for the U.S., Europe and Pacific Rim.
Mr. Kuras is co-founder of AxioMed Spine Corp. He previously held the position of Senior Vice President and Chief Technology Officer responsible for the development of the Freedom™ Lumbar Disc (FLD) System, the next generation of total disc replacement and first implant system in the Company's pipeline. He holds a number of key patents in orthopedics. His career includes positions at such notable companies as AcroMed, Sheridan Catheter and North American Instrument Corp.
Mr. Baty has over 15 years experience in finance, accounting, legal, human resources, administration and business operations. He has assisted small pharmaceutical and biotechnology companies raise funding through various vehicles, including public offerings, PIPEs, private venture financing, debt and grants.
Prior to joining AxioMed, Mr. Baty was Chief Financial Officer for Mt. Cook Pharma, a pharmaceutical development company focused in Urology. Before that, he served as Vice President of Finance, Secretary and Treasurer for Transave, Inc., a pharmaceutical company focused on the site specific treatment of lung disease and located in Princeton, NJ. Mr. Baty also served as Senior Director of Finance for Novazyme Pharmaceuticals, including holding the same position in a subsidiary of Genzyme Corporation after the merger of the two companies in late 2001. Prior to that, he served as Controller for Texas Biotechnology Corporation, later Encysive Pharmaceuticals, a public company in Houston, Texas, prior to its acquisition by Pfizer.
Mr. Baty holds a B.B.A. in accounting from Stephen F. Austin, an M.B.A. from the University of Houston and a J.D. from South Texas College of Law. He is a licensed CPA in Texas and is licensed to practice law in New York. Mr. Baty also serves on the board of directors for Shelbie.org, a not-for-profit organization dedicated to assisting families of patients suffering from Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig´s Disease).
Mr. Defibaugh has 15 years of medical device clinical and regulatory experience focused in orthopedic devices. He has clinical and regulatory experience in both class II and III devices obtaining marketing clearance/approval in the US and international markets.
Mr. Defibaugh joins AxioMed from Smith & Nephew, Inc., Orthopedic Division, where he most recently served as Director of Clinical Affairs. Mr. Defibaugh started his orthopedic medical device career at Smith & Nephew in 1992 and advanced through positions of increasing responsibility in clinical and regulatory affairs. He has direct experience with accomplishment in managing varied orthopedic product's pathways from clinical investigation through regulatory approval including numerous post-market and FDA regulated studies as well as success in FDA PMA approvals. Prior to Smith & Nephew, Mr. Defibaugh was employed by the University of Tennessee Medical Group in a clinical research capacity. Mr. Defibaugh holds a B.S. in Biology from Rhodes College (Memphis, TN).